Benjamin Landry Sells 2,500 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT) General Counsel Benjamin Landry sold 2,500 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $7.52, for a total transaction of $18,800.00. Following the completion of the transaction, the general counsel now owns 72,250 shares of the company’s stock, valued at approximately $543,320. The trade was a 3.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Benjamin Landry also recently made the following trade(s):

• On Friday, December 6th, Benjamin Landry sold 19,268 shares of Health Catalyst stock. The shares were sold at an average price of $8.32, for a total transaction of $160,309.76.

Health Catalyst Stock Down 6.4 %

Shares of NASDAQ HCAT traded down $0.47 during trading hours on Friday, hitting $6.89. The stock had a trading volume of 477,428 shares, compared to its average volume of 533,036. The company has a market capitalization of $419.24 million, a P/E ratio of -5.10 and a beta of 1.36. The firm’s 50-day moving average price is $7.81 and its two-hundred day moving average price is $7.52. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a 52 week low of $5.42 and a 52 week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the company earned ($0.22) EPS. Analysts anticipate that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Health Catalyst

Several institutional investors have recently bought and sold shares of the stock. Franklin Resources Inc. increased its holdings in shares of Health Catalyst by 5.8% during the 3rd quarter. Franklin Resources Inc. now owns 104,141 shares of the company’s stock valued at $857,000 after acquiring an additional 5,687 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Health Catalyst by 4.9% in the third quarter. Geode Capital Management LLC now owns 1,443,036 shares of the company’s stock valued at $11,749,000 after purchasing an additional 66,896 shares during the period. Zacks Investment Management raised its position in shares of Health Catalyst by 6.7% in the third quarter. Zacks Investment Management now owns 296,121 shares of the company’s stock valued at $2,410,000 after purchasing an additional 18,677 shares during the period. State Street Corp lifted its stake in shares of Health Catalyst by 2.5% in the third quarter. State Street Corp now owns 1,163,754 shares of the company’s stock worth $9,473,000 after buying an additional 28,251 shares during the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Health Catalyst during the 3rd quarter worth $84,000. 85.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research firms have weighed in on HCAT. Royal Bank of Canada lifted their price objective on shares of Health Catalyst from $8.00 to $9.00 and gave the stock a “sector perform” rating in a research report on Thursday, November 7th. Piper Sandler reiterated an “overweight” rating and set a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Evercore ISI increased their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Stephens raised their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research report on Thursday, November 14th. Finally, Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a report on Friday. Two equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to MarketBeat.com, Health Catalyst has a consensus rating of “Moderate Buy” and an average target price of $11.45.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.